Megan S Bradley1, Camila Cabrera2, Stephanie Glass Clark1, Jessica Sassani1, Kristen Venuti2, Mary F Ackenbom1. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Urogynecology and Reconstructive Pelvic Surgery Women's Center for Bladder and Pelvic Health, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 2. Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Women's Hospital, University of Pittsburgh Medical Center Pittsburgh, Pennsylvania.
Abstract
AIMS: To describe the uropathogens and antimicrobial resistance patterns in women with singular, sporadic urinary tract infection (UTI) vs those with recurrent UTI (rUTI) in a urogynecologic population. METHODS: This was a cross-sectional analysis of women treated for a UTI by a urogynecologic provider in a 1-year timeframe. Subjects were divided into two groups: (a) sporadic UTI-no history of rUTI and a single infection in the study timeframe and (b) rUTI-history of rUTI and ≥2 UTIs in the study timeframe. Our primary outcome was the difference in uropathogens between groups. Secondary aims were to investigate host characteristics associated with recurrent Escherichia coli infections and resistant uropathogens in the rUTI cohort. RESULTS: We had 265 women with 163 (61.5%) in the sporadic UTI group and 102 (38.5%) in the rUTI group. The most common uropathogens were E. coli (57.3%) and Klebsiella (11.7%). In the rUTI group, only 27 of 102 (26.5%) had all E. coli infections. There were differences between groups regarding age (P = .03) and proportion of neurogenic bladder (P = .01), intermittent self-catheterization (P < .01), antibiotic suppression (P < .01), and vaginal estrogen therapy (P < .01). In the rUTI cohort, there were no risk factors that were significantly associated with recurrent E.coli UTIs and vaginal estrogen therapy was associated with a higher odds of sensitive uropathogens (adjusted odds ratio, 3.12; confidence interval, 1.28-7.56). CONCLUSIONS: In those with rUTI, it was uncommon to have recurring E. coli UTIs and consistently sensitive uropathogens. Pretreatment urine cultures are important to verify causative uropathogens in this population.
AIMS: To describe the uropathogens and antimicrobial resistance patterns in women with singular, sporadic urinary tract infection (UTI) vs those with recurrent UTI (rUTI) in a urogynecologic population. METHODS: This was a cross-sectional analysis of women treated for a UTI by a urogynecologic provider in a 1-year timeframe. Subjects were divided into two groups: (a) sporadic UTI-no history of rUTI and a single infection in the study timeframe and (b) rUTI-history of rUTI and ≥2 UTIs in the study timeframe. Our primary outcome was the difference in uropathogens between groups. Secondary aims were to investigate host characteristics associated with recurrent Escherichia coliinfections and resistant uropathogens in the rUTI cohort. RESULTS: We had 265 women with 163 (61.5%) in the sporadic UTI group and 102 (38.5%) in the rUTI group. The most common uropathogens were E. coli (57.3%) and Klebsiella (11.7%). In the rUTI group, only 27 of 102 (26.5%) had all E. coli infections. There were differences between groups regarding age (P = .03) and proportion of neurogenic bladder (P = .01), intermittent self-catheterization (P < .01), antibiotic suppression (P < .01), and vaginal estrogen therapy (P < .01). In the rUTI cohort, there were no risk factors that were significantly associated with recurrent E.coli UTIs and vaginal estrogen therapy was associated with a higher odds of sensitive uropathogens (adjusted odds ratio, 3.12; confidence interval, 1.28-7.56). CONCLUSIONS: In those with rUTI, it was uncommon to have recurring E. coli UTIs and consistently sensitive uropathogens. Pretreatment urine cultures are important to verify causative uropathogens in this population.
Authors: Mariëlle A J Beerepoot; Gerben ter Riet; Sita Nys; Willem M van der Wal; Corianne A J M de Borgie; Theo M de Reijke; Jan M Prins; Jeanne Koeijers; Annelies Verbon; Ellen Stobberingh; Suzanne E Geerlings Journal: Arch Intern Med Date: 2012-05-14
Authors: James H Tabibian; Jeffrey Gornbein; Arash Heidari; Sarah L Dien; Valerie H Lau; Puneet Chahal; Bernard M Churchill; David A Haake Journal: J Clin Microbiol Date: 2008-10-08 Impact factor: 5.948
Authors: Anne M Suskind; Christopher S Saigal; Janet M Hanley; Julie Lai; Claude M Setodji; J Quentin Clemens Journal: Urology Date: 2016-01-26 Impact factor: 2.649
Authors: Pawel Miotla; Katarzyna Romanek-Piva; Michal Bogusiewicz; Ewa Markut-Miotla; Aneta Adamiak; Andrzej Wróbel; Małgorzata Zebrowska; Sara Wawrysiuk; Katarzyna Mendyk; Ewa Rechberger; Agata Jakubczak; Tomasz Rechberger Journal: Biomed Res Int Date: 2017-04-13 Impact factor: 3.411
Authors: Nicole A Meckes; Alexandra I Melnyk; Marina Guirguis; Halina Zyczynski; Megan S Bradley Journal: Female Pelvic Med Reconstr Surg Date: 2022-04-15 Impact factor: 1.913